Updates are available Correction dated 2023-07-06

Article History

Received: 25 August 2022

Accepted: 2 June 2023

First Online: 16 June 2023

Change Date: 6 July 2023

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1186/s12886-023-03065-2

Declarations

:

: The trial was approved by the institutional review board or ethics committee at each of 1315 sites in 57 countries (full list in the Additional file : Appendix). Participants provided written informed consent. The trial was conducted in accordance with the principles of the Declaration of Helsinki.

: Not applicable.

: Dr Suc reports no disclosures. Dr Schwartz reports research grants to the University of Colorado from Astra Zeneca, Resverlogix, Silence Therapeutics, Sanofi, and The Medicines Company; editorial support from Sanofi; research grants from the US Department of Veterans Affairs; and is coinventor of pending US patent 62/806,313 (“Methods for Reducing Cardiovascular Risk”) assigned in full to the University of Colorado. Dr Goodman reports research grant support (e.g., steering committee or data and safety monitoring committee) and/or speaker/consulting honoraria (e.g., advisory boards) from: Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CSL Behring, Daiichi-Sankyo/American Regent, Eli Lilly, Esperion, Ferring Pharmaceuticals, GlaxoSmithKline, HLS Therapeutics, JAMP Pharma, Janssen/Johnson & Johnson, Merck, Novartis, Novo Nordisk A/C, Pendopharm, Pfizer, Regeneron, Sanofi, Servier, Valeo Pharma; and salary support/honoraria from the Heart and Stroke Foundation of Ontario/University of Toronto (Polo) Chair, Canadian Heart Research Centre and MD Primer, Canadian VIGOUR Centre, Cleveland Clinic Coordinating Centre for Clinical Research, Duke Clinical Research Institute, New York University Clinical Coordinating Centre, and PERFUSE Research Institute. Dr Jukema reports research grants from the Netherlands Heart Foundation, the Interuniversity Cardiology Institute of the Netherlands, and the European Commission Seventh Framework Programme; and research support from Amgen, Astellas, AstraZeneca, Daiichi- Sankyo, Lilly, Merck-Schering-Plough, Pfizer, Roche, and Sanofi. Dr Manvelian is an employee of Regeneron Pharmaceuticals, Inc., and may hold shares and/or stock options in the company. Mr Poulouin is an IT&M Stats employee and IT&M Stats reports consultancy fees from Sanofi. Dr Pordy is an employee of Regeneron Pharmaceuticals, Inc., and may hold shares and/or stock options in the company. Dr Scemama is an employee of Sanofi may hold shares and/or stock options in the company. Dr Szarek reports serving as a consultant or on advisory boards (or both) for CiVi, Resverlogix, Baxter, Esperion, Sanofi, and Regeneron Pharmaceuticals, Inc. Dr Steg reports grants, personal fees, and non-financial support from Sanofi; grants and personal fees from Amarin, Servier and Bayer; personal fees from Amgen, AstraZeneca, BMS, Boehringer Ingelheim, Idorsia, Pfizer, and Novartis. In addition, Dr Steg has a patent use of alirocumab to reduce risk after ACS (royalties to Sanofi) pending.